Table 2.
Summary of all studies on HBOT for AAT(Bayoumy and de Ru, 2019; van der Veen et al., 2014). PF: pentoxifylline, Dx: dextran, VD: vasodilators, OS: oral steroids, IVS: intravenous steroids, PT: piracetam, NBOT: normobaric oxygen therapy, HBOT: hyperbaric oxygen therapy, IV: intravenous, MT: medical therapy, NA: not available.
| Author, year | Groups that included HBOT | Groups that did not include HBOT | Absolute hearing gain (dB) | Relative hearing gain (%) |
|---|---|---|---|---|
| Current analysis, 2021 | HBOT + OS | None | 24.5 dB | 58.4% |
| Bayoumy (Bayoumy et al., 2020), 2019 | HBOT + OS | OS | HBOT + OS: 23.5 dB OS: 12.5 dB |
HBOT + OS: 57.6% OS: 31.4% |
| Oya (Oya et al., 2019), 2019 | 1: HBOT + OS 2: HBOT - OS |
None | NA | HBOT + OS: 42.5% HBOT - OS: 25.4% |
| Van Haesendonck (Van Haesendonck et al., 2018), 2018 | HBOT + OS | OS | HBOT: 2.5 dB OS: 3.0 dB |
NA |
| Salihoğlu (Salihoğlu et al., 2015), 2015 | 1: HBOT + OS ≤ 10d 2: HBOT + OS > 10d |
None | NA | NA |
| Bonfort (Bonfort et al., 2014), 2014 | HBOT + IVS + PF | None | 18.3 dB | 53.8% |
| Lafère (Lafère et al., 2010), 2010 | 1: HBOT (o.d.for 10 days) + OS + PT 2: HBOT (b.d. for three days, followed by o.d. for 7 days) + IVS + PT IV |
MT: OS + PT | 1: 17.0 dB 2: 20.6 dB MT: 5.6 dB |
NA |
| Ylikoski (Ylikoski et al., 2008), 2008 | HBOT | NBOT | NA | PTA (0.5, 1, 2 kHz) HBOT: 74.1% NBOT: 60.2% P < 0.001 PTA (4, 6, 8 kHz) HBOT: 69.3% NBOT: 56.2% P < 0.001 |
| Winiarski (Winiarski et al., 2005), 2005 | HBOT + PT | None | NA | NA |
| Vavrina (Vavrina and Müller, 1995), 1995 | HBOT + OS + Dx | OS + Dx | NA | NA |
| Pilgramm (Pilgramm and Schumann, 1985), 1985 | HBOT + Sorbitol + Dx + betahistine | None | NA | NA |
| Demaertelare (Demaertelaere and Van Opstal, 1981), 1981 | HBOT | None | NA | NA |
| De Heyn (De Heyn and Van Opstal, 1976), 1976 | HBOT + VD | VD | NA | NA |